Search

Danaher Corp

Closed

SectorHealthcare

179.48 1.25

Overview

Share price change

24h

Current

Min

164.85

Max

201.54

Key metrics

By Trading Economics

Income

-168M

1B

Sales

-887M

6B

P/E

Sector Avg

38.576

60.149

EPS

2.06

Dividend yield

0.69

Profit margin

17.291

Employees

58,000

EBITDA

-560M

1.5B

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+14.09% upside

Dividends

By Acuity

Dividend yield

Sector Avg

0.69%

2.24%

Next Earnings

21 lip 2026

Next Dividend date

31 lip 2026

Next Ex Dividend date

25 wrz 2026

Market Stats

By TradingEconomics

Market Cap

2.5B

141B

Previous open

178.23

Previous close

179.48

News Sentiment

By Acuity

63%

37%

290 / 340 Ranking in Healthcare

Danaher Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

20 lip 2026, 23:41 UTC

Danaher Corp shares declined in after-market trading, continuing a trend of lower finishes amid concerns over economic momentum and a drop in the leading economic index.

Peer Comparison

Price change

Danaher Corp Forecast

Price Target

By TipRanks

14.09% upside

12 Months Forecast

Average 229.44 USD  14.09%

High 270 USD

Low 184.04 USD

Based on 18 Wall Street analysts offering 12 month price targets forDanaher Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

18 ratings

15

Buy

3

Hold

0

Sell

Sentiment

By Acuity

290 / 340 Ranking in Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.
help-icon Live chat